Comparison

AMGEN INC (AMGN) vs BIOGEN INC. (BIIB)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

AMGN

AMGEN INC

Drug Manufacturers—General

Revenue, FY25: $36.75B
Net income: $7.71B
Operating cash flow: $9.96B
Free cash flow: $8.1B
Net margin: 20.98%
Operating margin: 24.71%
Gross margin: 67.25%

BIIB

BIOGEN INC.

Drug Manufacturers—General

Revenue, FY25: $9.89B
Net income: $1.29B
Operating cash flow: $2.2B
Free cash flow: $2.05B
Net margin: 13.07%
Operating margin: -
Gross margin: 75.69%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	AMGN	BIIB
Revenue growth, latest filed year	+9.95%	+2.22%
Piotroski F-score	7 of 9	5 of 9
P/E against its own history	about normal	40.62% above

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

AMGN

FDA approval
Reimbursement
Cybersecurity
Litigation
China
Tax

And 20 more.

BIIB

FDA approval
Reimbursement
Tax
Litigation
Data privacy
Cybersecurity

And 19 more.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.04% · 0.14%

Updated Aug 5, 2026 · the newer of the two companies' filings